Thromb Haemost 2009; 101(03): 594-595
DOI: 10.1160/TH08-07-0465
Letters to the Editor
Schattauer GmbH

Thrombin generation test in patients under anticoagulant therapy with vitamin k antagonists

Isabel Brocal
1   Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain
,
Pascual Marco
1   Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain
,
Javier Lucas
1   Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain
,
José Verdú
1   Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain
,
Fabián Tarín
1   Thrombosis and Haemostasis Unit, University General Hospital of Alicante, Alicante, Spain
› Author Affiliations
Further Information

Publication History

Received: 22 July 2008

Accepted after minor revision: 05 February 2008

Publication Date:
24 November 2017 (online)

 

 
  • References

  • 1 Lassen JF, Kjeldsen J, Antonsen S. et al. Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anticoagulant therapy. Clin Chem 1995; 41: 1171-1176.
  • 2 Hemker HC, Al Dieri R, De Smedt E. et al. Thrombin generation, a function test of the haemostaticthrombotic system. Thromb Haemost 2006; 96: 553-561.
  • 3 Gatt A, van Veen JJ, Woolley AM. et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
  • 4 Dempfle CE, Borggrefe M. Do we need thrombin generation assays for monitoring anticoagulation?. Thromb Haemost 2008; 100: 179-180.
  • 5 Gerotziafas GT, Depasse F, Busson J. et al. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 2005; 3: 16.
  • 6 Wielders S, Mukherjee M, Michiels J. et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-636.
  • 7 Altman R, Scazziota A, Herrera L. et al. Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy. J Thromb Haemost 2007; 5: 1552-1569.
  • 8 Chantarangkul VCM, Bressi C, Giesen P. et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypocoagulability. Haematologica 2003; 88: 547-554.
  • 9 ten Cate-Hoek AJ, Dielis AW, Spronk HM. et al. Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost 2008; 100: 240-245.
  • 10 Hron G, Kollars M, Binder BR. et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
  • 11 Besser M, Baglin C, Luddington R. et al. High rate of unprovoked recurrent venous thrombosis is associated with a high thrombin generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-1725.
  • 12 Orbe J, Zudaire M, Serrano R. et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008; 99: 382-387.